Acute Lymphoblastic Leukemia Clinical Trials in Salt Lake City, Utah

4 studies are recruiting for acute lymphoblastic leukemia in Salt Lake City, Utah right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymph...

   Background: Chimeric antigen receptor T-cell (CART) therapy is a form of immunotherapy which can be used to treat people with relapsed B-ALL. For those who achieve remission after CART alone, it may cure up to 50% of people who receive this therapy. However, for people who relapse after CART, it ca…

   Stage

   Not phased

   Ages

   1 to 25

   Site

   Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah

   Locations

   8 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT05621291 on ClinicalTrials.gov

2. A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

   Phase 1 dose escalation will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of revumenib in participants with acute leukemia. In Phase 2, participants will be enrolled in 4 indication-specific expansion cohorts to determine the efficacy, short- and long-term safety, …

   Stage

   Phase 1

   Ages

   0 and older

   Site

   Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah

   Locations

   57 in total

   Run by

   Syndax Pharmaceuticals

   See if you can join NCT04065399 on ClinicalTrials.gov

3. Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies

   This is an open label, non-randomized, phase 1 study of anti-CD19 CAR-T cells against relapsed CD19 positive NHL, CLL and ALL based in a lymphodepletion regimen (fludarabine and cyclophosphamide) and using a CellReGen-based process for manufacturing CAR-T cells. This study will utilize a staggered …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Huntsman Cancer Institute, Salt Lake City, Utah

   Run by

   University of Utah

   See if you can join NCT06227026 on ClinicalTrials.gov

4. The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

   This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back after treatment or is difficult to treat may provide informat…

   Stage

   Phase 1

   Ages

   Up to 22

   Site

   Primary Children's Hospital, Salt Lake City, Utah

   Locations

   184 in total

   Run by

   PedAL BCU, LLC

   See if you can join NCT04726241 on ClinicalTrials.gov